{"id":"amg-410","safety":{"commonSideEffects":[{"rate":"34%","effect":"Fatigue"},{"rate":"31%","effect":"Nausea"},{"rate":"28%","effect":"Diarrhea"},{"rate":"24%","effect":"Vomiting"},{"rate":"21%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AMG 410 is a monoclonal antibody-drug conjugate that targets FGFR3, a receptor tyrosine kinase involved in the proliferation and survival of cancer cells.","oneSentence":"Antibody-drug conjugate targeting fibroblast growth factor receptor 3 (FGFR3)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:54:01.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07094113","phase":"PHASE1","title":"AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-07-31","conditions":"KRAS Altered Advanced or Metastatic Solid Tumors","enrollment":434}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AMG 410","genericName":"AMG 410","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antibody-drug conjugate targeting fibroblast growth factor receptor 3 (FGFR3) Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}